Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

c-MET-targeted antibody-drug conjugate

DRUG CLASS:

c-MET-targeted antibody-drug conjugate

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

EGFR wild-type + MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type + MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	telisotuzumab vedotin-tllv Sensitive: B - Late Trials telisotuzumab vedotin-tllv Sensitive : B	telisotuzumab vedotin-tllv Sensitive: B - Late Trials telisotuzumab vedotin-tllv Sensitive : B
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	MYTX-011 Sensitive: B - Late Trials MYTX-011 Sensitive : B	MYTX-011 Sensitive: B - Late Trials MYTX-011 Sensitive : B
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	erlotinib + telisotuzumab vedotin-tllv Sensitive: C2 – Inclusion Criteria erlotinib + telisotuzumab vedotin-tllv Sensitive : C2	erlotinib + telisotuzumab vedotin-tllv Sensitive: C2 – Inclusion Criteria erlotinib + telisotuzumab vedotin-tllv Sensitive : C2
MET positive	Non Small Cell Lung Cancer	MET positive	Non Small Cell Lung Cancer	telisotuzumab vedotin-tllv Sensitive: C2 – Inclusion Criteria telisotuzumab vedotin-tllv Sensitive : C2	telisotuzumab vedotin-tllv Sensitive: C2 – Inclusion Criteria telisotuzumab vedotin-tllv Sensitive : C2
MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	telisotuzumab vedotin-tllv Sensitive: C2 – Inclusion Criteria telisotuzumab vedotin-tllv Sensitive : C2	telisotuzumab vedotin-tllv Sensitive: C2 – Inclusion Criteria telisotuzumab vedotin-tllv Sensitive : C2
MET expression	Solid Tumor	MET expression	Solid Tumor	BYON3521 Sensitive: C2 – Inclusion Criteria BYON3521 Sensitive : C2	BYON3521 Sensitive: C2 – Inclusion Criteria BYON3521 Sensitive : C2
MET amplification	Solid Tumor	MET amplification	Solid Tumor	ABBV-400 Sensitive: C2 – Inclusion Criteria ABBV-400 Sensitive : C2	ABBV-400 Sensitive: C2 – Inclusion Criteria ABBV-400 Sensitive : C2
MET positive	Lung Non-Squamous Non-Small Cell Cancer	MET positive	Lung Non-Squamous Non-Small Cell Cancer	erlotinib + telisotuzumab vedotin-tllv Sensitive: C3 – Early Trials erlotinib + telisotuzumab vedotin-tllv Sensitive : C3	erlotinib + telisotuzumab vedotin-tllv Sensitive: C3 – Early Trials erlotinib + telisotuzumab vedotin-tllv Sensitive : C3
MET positive	Lung Non-Small Cell Squamous Cancer	MET positive	Lung Non-Small Cell Squamous Cancer	erlotinib + telisotuzumab vedotin-tllv Sensitive: C3 – Early Trials erlotinib + telisotuzumab vedotin-tllv Sensitive : C3	erlotinib + telisotuzumab vedotin-tllv Sensitive: C3 – Early Trials erlotinib + telisotuzumab vedotin-tllv Sensitive : C3
EGFR mutation	Lung Non-Small Cell Squamous Cancer	EGFR mutation	Lung Non-Small Cell Squamous Cancer	erlotinib + telisotuzumab vedotin-tllv Sensitive: C3 – Early Trials erlotinib + telisotuzumab vedotin-tllv Sensitive : C3	erlotinib + telisotuzumab vedotin-tllv Sensitive: C3 – Early Trials erlotinib + telisotuzumab vedotin-tllv Sensitive : C3
MET overexpression + EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	MET overexpression + EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	telisotuzumab vedotin-tllv Sensitive: C3 – Early Trials telisotuzumab vedotin-tllv Sensitive : C3	telisotuzumab vedotin-tllv Sensitive: C3 – Early Trials telisotuzumab vedotin-tllv Sensitive : C3
MET overexpression + EGFR mutation	Non Small Cell Lung Cancer	MET overexpression + EGFR mutation	Non Small Cell Lung Cancer	osimertinib + telisotuzumab vedotin-tllv Sensitive: C3 – Early Trials osimertinib + telisotuzumab vedotin-tllv Sensitive : C3	osimertinib + telisotuzumab vedotin-tllv Sensitive: C3 – Early Trials osimertinib + telisotuzumab vedotin-tllv Sensitive : C3